miRNAs与非小细胞肺癌EGFR突变及放疗相关性研究进展

Research advances in the association of miRNAs with EGFR mutation, EGFR-TKI, and radiotherapy in non-small cell lung cancer

EGFR作为NSCLC靶向治疗的热点,近年来其在分子生物学水平的研究众多。而放疗作为一种NSCLC重要的传统治疗方法,其疗效与EGFR突变及过表达相关。放疗联合EGFR-TKI在NSCLC治疗上的疗效还缺乏Ⅲ期临床结果。miRNAs能够调控肿瘤相关基因表达,影响肿瘤生物学活动。近来研究显示miRNAs对EGFR突变、EGFR-TKI和放疗均存在正向或负向的调控作用,其具体机制已部分阐明。现就miRNAs对EGFR突变、EGFR-TKI及放疗间相关性作一综述,旨在为miRNAs应用于放疗联合EGFR-TKI治疗NSCLC提供最新诊疗依据。

Epidermal growth factor receptor （EGFR） is most popular in targeted therapy for non-small cell lung cancer （NSCLC）. In recent years, there have been a great number of molecular biology studies of EGFR. Radiotherapy is well-known as a traditional and important treatment for NSCLC, and the treatment outcome is associated with EGFR mutation and overexpression. Phase Ⅲ trials are needed to evaluate the effect of a combination of radiotherapy and EGFR-tyrosine kinase inhibitor （EGFR-TKI） in the treatment of NSCLC. MicroRNAs （miRNAs） can modulate tumor-associated gene expression and influence the biological process of tumor. Recent studies have demonstrated that miRNAs play a positive or negative role in EGFR mutation, EGFR-TKI treatment, and radiotherapy, which mechanism has been partially clarified. In this article, we review the research advances in the association of miRNAs with EGFR mutation, EGFR-TKI, and radiotherapy, so as to provide the latest evidence for the application of miRNAs in the combination of radiotherapy and EGFR-TKI for the treatment of NSCLC.